CR20140224A - Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas - Google Patents
Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadasInfo
- Publication number
- CR20140224A CR20140224A CR20140224A CR20140224A CR20140224A CR 20140224 A CR20140224 A CR 20140224A CR 20140224 A CR20140224 A CR 20140224A CR 20140224 A CR20140224 A CR 20140224A CR 20140224 A CR20140224 A CR 20140224A
- Authority
- CR
- Costa Rica
- Prior art keywords
- immunoligants
- bispecific
- related applications
- directed against
- against tnf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
Abstract
Se proporcionan proteínas de unión multiespecíficas y multivalentes diseñadas, métodos de fabricación, y específicamente sus usos en la prevención, diagnóstico y/o tratamiento de la enfermedad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550619P | 2011-10-24 | 2011-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140224A true CR20140224A (es) | 2014-09-03 |
Family
ID=47144148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20140224A CR20140224A (es) | 2011-10-24 | 2014-05-14 | Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas |
Country Status (25)
Country | Link |
---|---|
US (2) | US9655964B2 (es) |
EP (1) | EP2771361A1 (es) |
JP (1) | JP6121432B2 (es) |
KR (1) | KR20140084254A (es) |
CN (1) | CN104185641A (es) |
AR (1) | AR088514A1 (es) |
AU (1) | AU2012328917B2 (es) |
BR (1) | BR112014009810A2 (es) |
CA (1) | CA2853114A1 (es) |
CL (1) | CL2014001055A1 (es) |
CO (1) | CO7020874A2 (es) |
CR (1) | CR20140224A (es) |
DO (1) | DOP2014000084A (es) |
EC (1) | ECSP14001260A (es) |
GT (1) | GT201400077A (es) |
HK (1) | HK1200321A1 (es) |
IL (1) | IL232207A0 (es) |
MX (1) | MX2014004980A (es) |
PE (1) | PE20142245A1 (es) |
RS (1) | RS20140202A1 (es) |
RU (1) | RU2014121043A (es) |
SG (1) | SG11201401796SA (es) |
TW (1) | TW201323441A (es) |
UY (1) | UY34410A (es) |
WO (1) | WO2013063110A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105131112A (zh) | 2009-08-29 | 2015-12-09 | Abbvie公司 | 治疗用dll4结合蛋白 |
RU2016146198A (ru) | 2010-03-02 | 2018-12-19 | Эббви Инк. | Терапевтические dll4-связывающие белки |
CN102906118B (zh) | 2010-05-20 | 2017-07-28 | 埃博灵克斯股份有限公司 | 与her3相关的生物材料 |
BR112013002578A2 (pt) | 2010-08-03 | 2019-05-14 | Abbvie Inc. | imunoglobinas de domínio variável duplo e usos das mesmas |
AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
BR112014009799A2 (pt) | 2011-10-24 | 2017-06-13 | Abbvie Inc | imunoligantes dirigidos conra tnf |
US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
RU2017137740A (ru) | 2012-11-01 | 2019-02-11 | Эббви Инк. | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения |
AU2014227664A1 (en) * | 2013-03-15 | 2015-09-24 | Abbvie Inc. | Dual specific binding proteins directed against TNFalpha |
LT3072905T (lt) * | 2013-11-18 | 2020-12-10 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-17a surišantis agentas ir jo panaudojimas |
IL292311A (en) | 2014-04-03 | 2022-06-01 | Igm Biosciences Inc | J-chain qualified |
WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
WO2015191760A2 (en) * | 2014-06-10 | 2015-12-17 | Abbvie, Inc. | Compositions and methods for treating rheumatoid arthritis |
JP6663910B2 (ja) * | 2014-08-26 | 2020-03-13 | アムジェン ケー・エー,インコーポレイテッド | 抗TNF−α抗体療法を受けた乾癬患者を治療するための方法 |
MY192824A (en) | 2014-09-03 | 2022-09-12 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
GB201500463D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
SG10202001779UA (en) | 2015-01-20 | 2020-04-29 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
CA2999284C (en) | 2015-09-30 | 2023-06-13 | Igm Biosciences A/S | Binding molecules with modified j-chain |
AU2016335017A1 (en) * | 2015-10-05 | 2018-03-29 | Galapagos Nv | Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis |
MY196756A (en) | 2015-12-14 | 2023-05-03 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
EP3408293A4 (en) * | 2016-01-28 | 2019-09-11 | Janssen Biotech, Inc. | BISPECIFIC ANTI-TNF-ALPHA / IL-17A ANTIBODY ANTIBODIES AND ANTI-TNF-ALPHA ANTIBODIES AND METHODS OF USE |
RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
RU2745748C2 (ru) | 2016-06-02 | 2021-03-31 | Эббви Инк. | Агонист глюкокортикоидного рецептора и его иммуноконъюгаты |
EP3538141A4 (en) * | 2016-11-10 | 2020-07-15 | Merck Sharp & Dohme Corp. | ILT3 LIGAND |
EP3684801A1 (en) * | 2017-09-22 | 2020-07-29 | H. Hoffnabb-La Roche Ag | Multivalent mono- or bispecific recombinant antibodies for analytic purpose |
MA49796A (fr) | 2017-12-01 | 2020-06-03 | Abbvie Inc | Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci |
US20220127350A1 (en) | 2019-01-31 | 2022-04-28 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
EP3980448A4 (en) * | 2019-06-04 | 2023-06-28 | Academia Sinica | Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
CN112375149B (zh) * | 2020-10-30 | 2023-04-18 | 沣潮医药科技(上海)有限公司 | Ace2免疫融合蛋白及其应用 |
WO2023091968A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
SE462454B (sv) | 1988-11-10 | 1990-06-25 | Pharmacia Ab | Maetyta foer anvaendning i biosensorer |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
US5135875A (en) | 1990-08-15 | 1992-08-04 | Abbott Laboratories | Protein precipitation reagent |
CA2048302A1 (en) | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
CA2131727A1 (en) | 1992-03-30 | 1993-10-14 | Diana E. Clarisse | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
CN101712720A (zh) | 1996-02-09 | 2010-05-26 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
ATE340870T1 (de) | 1998-04-03 | 2006-10-15 | Compound Therapeutics Inc | Adressierbare protein arrays |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000056934A1 (en) | 1999-03-24 | 2000-09-28 | Packard Bioscience Company | Continuous porous matrix arrays |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
IL153567A0 (en) | 2000-06-29 | 2003-07-06 | Abbott Lab | Dual specificity antibodies and methods of making and using |
US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
RU2377253C2 (ru) | 2002-12-02 | 2009-12-27 | Амген Фремонт,Инк. | Антитела, специфичные к фактору некроза опухолей, и их применение |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
PL1603541T5 (pl) | 2003-03-05 | 2013-06-28 | Halozyme Inc | Rozpuszczalna glikoproteina o aktywności hialuronidazy (sHASEGP), sposób jej wytwarzania, zastosowanie i zawierające ją kompozycje farmaceutyczne |
ES2586401T3 (es) | 2003-06-16 | 2016-10-14 | Ucb Pharma S.A. | Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea |
AU2004280333A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
WO2006014477A1 (en) | 2004-07-06 | 2006-02-09 | Bioren, Inc. | HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
WO2008133722A2 (en) | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
DK2131860T3 (da) | 2007-03-20 | 2014-01-13 | Lilly Co Eli | Anti-sclerostin-antistoffer |
US7906293B2 (en) | 2007-04-09 | 2011-03-15 | Abbott Laboratories | Acridinium phenyl esters useful in the analysis of biological |
TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
KR20100113112A (ko) | 2008-01-15 | 2010-10-20 | 아보트 러보러터리즈 | 개선된 포유동물 발현 벡터 및 이의 용도 |
WO2009149189A2 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
AR075798A1 (es) | 2009-03-05 | 2011-04-27 | Abbott Lab | Proteinas de union a il-17 (interleuquina 17) |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
MX2012011629A (es) | 2010-04-07 | 2013-03-05 | Abbvie Inc | Proteinas de union a tnf-alfa. |
BR112013002578A2 (pt) | 2010-08-03 | 2019-05-14 | Abbvie Inc. | imunoglobinas de domínio variável duplo e usos das mesmas |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
TW201323440A (zh) | 2011-10-24 | 2013-06-16 | Abbvie Inc | 抗骨硬化素(sclerostin)之免疫結合物 |
BR112014009799A2 (pt) | 2011-10-24 | 2017-06-13 | Abbvie Inc | imunoligantes dirigidos conra tnf |
-
2012
- 2012-10-24 BR BR112014009810A patent/BR112014009810A2/pt not_active IP Right Cessation
- 2012-10-24 WO PCT/US2012/061686 patent/WO2013063110A1/en active Application Filing
- 2012-10-24 KR KR1020147013797A patent/KR20140084254A/ko not_active Application Discontinuation
- 2012-10-24 EP EP12783474.5A patent/EP2771361A1/en not_active Withdrawn
- 2012-10-24 AR ARP120103979A patent/AR088514A1/es unknown
- 2012-10-24 US US13/659,666 patent/US9655964B2/en active Active
- 2012-10-24 JP JP2014538926A patent/JP6121432B2/ja active Active
- 2012-10-24 TW TW101139328A patent/TW201323441A/zh unknown
- 2012-10-24 CA CA2853114A patent/CA2853114A1/en not_active Abandoned
- 2012-10-24 CN CN201280064228.6A patent/CN104185641A/zh active Pending
- 2012-10-24 SG SG11201401796SA patent/SG11201401796SA/en unknown
- 2012-10-24 AU AU2012328917A patent/AU2012328917B2/en not_active Ceased
- 2012-10-24 UY UY0001034410A patent/UY34410A/es not_active Application Discontinuation
- 2012-10-24 RS RS20140202A patent/RS20140202A1/en unknown
- 2012-10-24 RU RU2014121043/10A patent/RU2014121043A/ru not_active Application Discontinuation
- 2012-10-24 PE PE2014000606A patent/PE20142245A1/es not_active Application Discontinuation
- 2012-10-24 MX MX2014004980A patent/MX2014004980A/es unknown
-
2013
- 2013-11-18 US US14/082,502 patent/US20140079705A1/en not_active Abandoned
-
2014
- 2014-04-23 IL IL232207A patent/IL232207A0/en unknown
- 2014-04-24 CL CL2014001055A patent/CL2014001055A1/es unknown
- 2014-04-24 DO DO2014000084A patent/DOP2014000084A/es unknown
- 2014-04-24 GT GT201400077A patent/GT201400077A/es unknown
- 2014-05-14 CR CR20140224A patent/CR20140224A/es unknown
- 2014-05-19 EC ECIEPI20141260A patent/ECSP14001260A/es unknown
- 2014-05-22 CO CO14110752A patent/CO7020874A2/es unknown
-
2015
- 2015-01-22 HK HK15100713.9A patent/HK1200321A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20140079705A1 (en) | 2014-03-20 |
AU2012328917A1 (en) | 2014-05-22 |
US9655964B2 (en) | 2017-05-23 |
CO7020874A2 (es) | 2014-08-11 |
BR112014009810A2 (pt) | 2017-04-25 |
WO2013063110A1 (en) | 2013-05-02 |
CL2014001055A1 (es) | 2014-08-18 |
GT201400077A (es) | 2014-12-23 |
IL232207A0 (en) | 2014-06-30 |
RS20140202A1 (en) | 2014-10-31 |
UY34410A (es) | 2013-05-31 |
ECSP14001260A (es) | 2015-07-31 |
PE20142245A1 (es) | 2015-01-22 |
SG11201401796SA (en) | 2014-10-30 |
US20140161804A1 (en) | 2014-06-12 |
JP6121432B2 (ja) | 2017-04-26 |
RU2014121043A (ru) | 2015-12-10 |
MX2014004980A (es) | 2014-09-11 |
DOP2014000084A (es) | 2014-09-15 |
AU2012328917B2 (en) | 2017-05-25 |
EP2771361A1 (en) | 2014-09-03 |
CN104185641A (zh) | 2014-12-03 |
TW201323441A (zh) | 2013-06-16 |
HK1200321A1 (en) | 2015-08-07 |
JP2015502145A (ja) | 2015-01-22 |
KR20140084254A (ko) | 2014-07-04 |
CA2853114A1 (en) | 2013-05-02 |
AR088514A1 (es) | 2014-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20140224A (es) | Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas | |
AR089529A1 (es) | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 | |
ECSP13012776A (es) | Inmunoglobulinas de dominio variable dual | |
UY35478A (es) | PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA IL-1ß y/o IL-17 | |
CL2014002342A1 (es) | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma. | |
ECSP15040888A (es) | PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA TNF alfa | |
CR20110631A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
CO6650372A2 (es) | Proteínas de unión de dominio variable dual que se unen a tnfy tweak, y métopdos para hacer y usar dichas proteínas | |
BR112013010857A2 (pt) | imonoglubulinas de duplo domínio variável e usos das mesmas | |
BR112013020259A2 (pt) | tratamento de osteoartrite e dores | |
ECSP13012462A (es) | Inmunoglobulinas con dominio variable dual | |
UY31861A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
UY33826A (es) | Proteínas de unión con dominios trivariables y sus usos | |
CR20120154A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
UY31862A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
CO6690781A2 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
CO6670524A2 (es) | Proteínas de unión de dominio variable dual que se unen a ngf y al menos a un blanco adicional, y métodos para hacer y usar dichas proteínas de unión | |
UY33707A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
GT201200109A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
BR112012009043A2 (pt) | imunoglobulinas de duplo domínio variável e sua utilização | |
FR2979346B1 (fr) | Nanocorps anti-vcam-1 | |
ECSP13012523A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
EA201301080A1 (ru) | Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания | |
CY1117740T1 (el) | Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης | |
UA109933C2 (uk) | Застосування солей 3-карбоксі-n-етил-n,n-диметилпропан-1-амінію в лікуванні серцево-судинної хвороби |